In general, ketamine treatment is prescribed for people with serious mental illnesses who have tried other medications with marginal or no success. It has been studied extensively in people with treatment-resistant depression and acute suicidality. It may also benefit patients with conditions such as PTSD, OCD, bipolar depression, anxiety, and eating disorders. Therapeutic ketamine is generally not recommended for people with certain conditions, such as psychosis.
On Monday, a study published in the Journal of Clinical Psychiatry of ketamine users at three clinics in Virginia showed a significant reduction in the reduction of depression. The evaluation of more than 400 patients at three Mind Peace ketamine clinics in Virginia showed that 72 percent of patients saw improvement in their mood and 38 percent were symptom-free after 10 infusions. The study, conducted by the ketamine clinics on a self-selecting group of patients, has its limitations. Ketamine therapy is most likely to be beneficial for who
Ketamine was approved as an anesthetic in 1970, but using it to address psychiatric conditions is considered “off-label.” That means it’s legal for a doctor to prescribe, but it’s not approved by the Food and Drug Administration for that particular indication.
The one exception is ketamine, a nasal spray approved by the FDA in 2019 and marketed as Spravato for treatment-resistant depression and acute suicidal thinking.Ketamine therapy is most likely to be beneficial for who
In the biggest advance for depression in years, FDA approves novel treatment for the hardest cases
Gerard Sanacora, a professor of psychiatry at the Yale School of Medicine, said that while ketamine can be “lifesaving” for some patients, many questions remain about the range of disorders it might help, the appropriate mode of delivery, optimal dosing, long-term safety. “It’s not a miracle treatment for everyone,” he said.